

and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel.

Date: April 19, 1999.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesda Holiday Inn, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Tommy L. Broadwater, PhD, Chief, Grants Review Branch, National Institutes of Health, NIAMS, Natcher Bldg., Room 5A525U, Bethesda, MD 20892, 301-594-4952.

Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel.

Date: April 29, 1999.

Time: 8:30 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn Bethesda, Delaware Room, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Barbara Detrick, PhD, Scientific Review Administrator, National Institutes of Health, MIAMS, Bldg. 45, Room 5A525N, Bethesda, MD 20892, 301-594-4952.

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS)

Dated: April 1, 1999.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 99-8667 Filed 4-7-99; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Office of AIDS Research Advisory Council.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Office of AIDS Research Advisory Council.

Date: April 28-29, 1999.

Time: 8:45 a.m. to 4:30 p.m.

Agenda: The Office of AIDS Research Advisory Council agenda includes Overview

of the HIV Prevention Science Agenda at NIH, NIH FY 2001 Plan for HIV-Related Research, and other Council business.

Place: National Institutes of Health, 9000 Rockville Pike, Building 31, Conference Room 6, Bethesda, MD 20892.

Contact Person: Linda Reck, Head, Program, Planning and Evaluation, Office of AIDS Research, NIH, Bethesda, MD 20892, (301) 403-8655.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program, National Institutes of Health, HHS)

Dated: March 31, 1999.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 99-8664 Filed 4-7-99; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Advisory Committee on Research on Women's Health.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Advisory Committee on Research on Women's Health.

Date: May 6, 1999.

Time: 1:30 PM to 6:00 PM.

Agenda: To provide advice to the Office of Research on Women's Health (ORWH) on its research agenda and to provide recommendations regarding ORWH activities.

Place: National Institutes of Health, Building 31, Conference Room 10, Bethesda, MD 20892.

Contact Person: Joyce Rudick, Director, Programs & Management, Office of Research on Women's Health, Office of the Director, National Institutes of Health, Building 1, Room 201, Bethesda, MD 20892, 301/402-1770.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.187, Undergraduate Scholarship Program for Individuals from

Disadvantage Backgrounds; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program, National Institutes of Health, HHS)

Dated: March 25, 1999.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 99-8669 Filed 4-7-99; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Public Health Service; Office of Research on Women's Health; Notice of Meeting—"Biologic & Molecular Mechanisms for Sex Differences in Pharmacokinetics, Pharmacodynamics and Pharmacogenetics"

Notice is hereby given that the Office of Research on Women's Health (ORWH), Office of the Director, National Institutes of Health (NIH), will convene a workshop on May 5, 1999, 8:30 am-5:45 pm; May 6, 1999 at 8:30 am-12:30 pm.

The research planning workshop will address current and future research on differences in the ways in which women and men respond to pharmacologic agents. This workshop will provide a forum for scientific discussion of the biologic and molecular mechanisms that underlie differences in the effects and action of drugs in women and men. While data are limited, studies have documented differences between women and men in the safety and effectiveness of some drugs and, on a molecular level, in differences in drug metabolizing enzymes. The workshop will feature scientific presentations that will delineate the current state of knowledge, identify emerging issues or continuing gaps in knowledge, and catalyze discussion of methods to assess and predict sex-based and individual variations in response to drugs. The program will feature leaders in the fields of pharmacokinetics, pharmacodynamics, pharmacogenetics, hormonal influences on drugs, and new technologies in drug development.

Also serving as co-sponsors of this research planning workshop are the Office of Women's Health of the U.S. Food and Drug Administration; National Heart, Lung and Blood Institute, National Human Genome Research Institute; National Institute on Aging;

National Institute of Child Health and Human Development; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Neurological Disorders and Stroke; and the Pain Consortium of the NIH.

Advance registration and confirmation of registration is required as seating is limited. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The workshop will be held at Lister Hill Auditorium, National Library of Medicine, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892. The contact person is Ms. Gloria Williams, KRA Corporation, 1010 Wayne Avenue, Suite 850, Silver Spring, Maryland 20910. To register please call Ms. Williams at (301) 562-2340.

Dated: March 30, 1999.

Ruth L. Kirschstein,

Deputy Director, NIH.

[FR Doc. 99-8671 Filed 4-7-99; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License; A₃ Adenosine Receptor Agonists and Antagonists

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license worldwide to practice the invention embodied in: U.S. Patent Applicant Serial No. 60/092,292 filed July 10, 1998 entitled "A₃ Adenosine Receptor Antagonist", PCT application US97/01252 filed January 29, 1997 designating the U.S. entitled "Dihydropyridine, Pyridine, Benzophenone and Triazoloquinazolinone Derivatives Their Preparation And Their Use As Adenosine Receptor Antagonists" and 08/091,109 filed July 13, 1993 and abandoned and refiled as 08/163,324 on December 6, 1993 also now abandoned

and refiled as 08/274,628 now issued as U.S. Patent No. 5,773,423 June 30, 1998 entitled "A₃ Adenosine Receptor Agonists", to Gilead Sciences, having a place of business in Foster City, California. The United States of America is the assignee of the patent rights in this invention.

DATES: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before July 7, 1999 will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Charles Maynard, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 496-7056, ext. 243; Facsimile: (301) 402-0220; E-mail: MaynardC@od.nih.gov.

SUPPLEMENTARY INFORMATION: In an effort to develop an efficacious treatment involving the collection of various technology involving Adenosine receptors, the inventors posit that Adenosine may play several key physiological roles. In addition to its role in intermediary metabolism, adenosine displays a number of receptor-mediated physiological actions, including dilation of coronary vessels, inhibition of platelet aggregation, and inhibition of lipolysis.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be limited to the field of human therapeutics and may be granted unless, within 90 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Property filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted to response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: March 30, 1999.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 99-8668 Filed 4-7-99; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, and Laboratories That Have Withdrawn From the Program

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A similar notice listing all currently certified laboratories will be published during the first week of each month, and updated to include laboratories which subsequently apply for and complete the certification process. If any listed laboratory's certification is totally suspended or revoked, the laboratory will be omitted from updated lists until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be identified as such at the end of the current list of certified laboratories, and will be omitted from the monthly listing thereafter.

This Notice is now available on the internet at the following website: <http://www.health.org/workpl.htm>

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl, Division of Workplace Programs, 5600 Fishers Lane, Rockwall 2 Building, Room 815, Rockville, Maryland 20857; Tel.: (301) 443-6014.

Special Note: Our office moved to a different building on May 18, 1998. Please use the above address for all regular mail and correspondence. For all overnight mail service use the following address: Division of Workplace Programs, 5515 Security Lane, Room 815, Rockville, Maryland 20852.

SUPPLEMENTARY INFORMATION: Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100-71. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an